Stock 603538 NINGBO MENOVO PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ningbo Menovo Pharmaceutical Co., Ltd.

Equities

603538

CNE100002Y25

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 28/06/2024 am IST 		5-day change 1st Jan Change
11.17 CNY +0.27% Intraday chart for Ningbo Menovo Pharmaceutical Co., Ltd. -2.87% -41.58%
26/06 Menovo Pharmaceutical Unit Gets Registration Certificate for Glucosamine Sulfate Capsules MT
24/05 China Approves Menovo Pharma's Type 2 Diabetes Drug MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's profit outlook over the next few years is a strong asset.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 10.44 for the current year.
  • The company appears to be poorly valued given its net asset value.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
NINGBO MENOVO PHARMACEUTICAL CO., LTD. Stock Ningbo Menovo Pharmaceutical Co., Ltd.
-41.58% 34Cr -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 82TCr
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 64TCr
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 35TCr
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 31TCr
B-
ABBVIE INC. Stock AbbVie Inc.
+10.68% 30TCr
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 24TCr
B+
NOVARTIS AG Stock Novartis AG
+13.31% 22TCr
B-
AMGEN INC. Stock Amgen Inc.
+8.48% 17TCr
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 16TCr
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 603538 Stock
  4. Ratings Ningbo Menovo Pharmaceutical Co., Ltd.